Group 1 - The company plans to repurchase shares through centralized bidding, with a total fund amount not less than 300 million and not exceeding 500 million [1] - The repurchase price will not exceed 65 yuan per share, and the repurchase period will not exceed 12 months [1] - The company's controlling shareholders, actual controllers, and senior management have no plans to reduce their holdings in the next 3 to 6 months [1] Group 2 - The repurchased shares will be used for the employee stock ownership plan [1] - There may be risks associated with the implementation of the repurchase plan as planned [1]

Group 1 - The company did not distribute cash dividends, issue bonus shares, or convert reserves into capital during the reporting period [3] - The company did not experience any changes in its controlling shareholder or actual controller during the reporting period [5][6] - The company held a board meeting on August 26, 2025, where all directors were present and approved the half-year report [2][16] Group 2 - The company reported a total fundraising amount of approximately 999.99 million yuan, with a net amount of approximately 976.65 million yuan after deducting issuance costs [30] - As of June 30, 2025, the balance of the fundraising special account was 0 yuan, indicating that all funds had been utilized [32][33] - The company has not used idle fundraising for temporary working capital or cash management during the reporting period [36][38] Group 3 - The company established a management committee for the second employee stock ownership plan, which was approved by the holders' meeting [22][24] - The management committee is responsible for the daily management of the employee stock ownership plan and has been authorized to handle various related matters [25][26] - The company completed the fundraising project and canceled all special fundraising accounts by the end of the reporting period [39][44]

Core Viewpoint - The report from Credit Lyonnais indicates that Fosun Pharma (02196) demonstrated resilience in its Q2 performance, with a quarterly revenue increase of 7.2% and a net profit increase of 22.5%, primarily driven by strong sales of innovative products [1] Group 1: Financial Performance - Revenue increased by 7.2% quarter-on-quarter [1] - Net profit increased by 22.5% quarter-on-quarter [1] Group 2: Growth Drivers - Strong performance attributed to the sales of innovative products [1] - The new Employee Stock Ownership Plan (ESOP) is expected to enhance growth visibility and alleviate market concerns following leadership changes [1] Group 3: Forecast and Valuation - Core profit forecasts for Fosun Pharma have been raised by approximately 13% to 21% for the years 2023 to 2027 [1] - The target price for H-shares has been increased from HKD 15.6 to HKD 29.6, maintaining an outperform rating [1] Group 4: Strategic Initiatives - The ESOP plan for senior management is linked to achieving a 20% compound annual growth rate for both innovative drug sales and net profit from 2023 to 2027 [1] - Successful completion of licensing agreements for two self-developed molecules [1]

里昂报告指，复星医药(02196.HK)第二季业绩具韧性，收入按季升7.2%，净利润按季升22.5%，主要受 惠于创新产品销售强劲表现。该行认为新的员工持股计划为其增长提供更大能见度，并部分舒缓领导层 变动后的市场担忧，该计划主要条件与今年至2027年创新药销售目标和净利润目标挂钩，意味两个指标 均实现20%年复合增长率；公司亦成功完成两款自主研发分子的对外授权交易。该行上调对复星医药今 年至2027年核心利润预测介乎约13%至21%，H股目标价由15.6港元上调至29.6港元，维持跑赢大市评 级。 ...

Core Viewpoint - Jindao Technology (301279) reported a significant increase in net profit for the first half of 2025, with plans to implement an employee stock ownership plan to enhance long-term development [1][2] Financial Performance - In the first half of 2025, the company achieved operating revenue of 352 million yuan, representing a year-on-year growth of 9.69% [1] - The net profit attributable to shareholders was 32.026 million yuan, reflecting a year-on-year increase of 46.35% [1] - The net profit after deducting non-recurring gains and losses was 30.039 million yuan, up by 37.97% year-on-year [1] Employee Stock Ownership Plan - The company plans to grant shares at a price of 12.67 yuan per share to no more than 50 directors, supervisors, and core personnel, with total funding not exceeding 5.7015 million yuan [1] - The stock involved in the employee stock ownership plan will be repurchased A-share common stock, with a cap of 450,000 shares, accounting for 0.35% of the total share capital [1][2] Industry Position and Strategy - Jindao Technology has been deeply involved in the forklift transmission industry for many years, offering a complete range of products and reliable quality [2] - The company is one of the first private enterprises in China to enter the forklift transmission field and is among the few that have penetrated the supply chains of internationally renowned forklift manufacturers [2] - The company has established partnerships with notable international clients such as Toyota, Mitsubishi, Doosan, Kion Group, and others [2] Innovation and Product Development - The company has continuously engaged in technological reforms and service expansion within the forklift transmission industry, enhancing product quality and establishing a comprehensive competitive advantage [2] - Jindao Technology is committed to launching high-end new products that align with industry trends, leveraging its design, development, and production technology [2] - The company has completed the prototype of its integrated electric drive product and is currently validating its electric drive axle products with customers [2]

Core Viewpoint - The report from Credit Lyonnais indicates that Fosun Pharma's Q2 performance shows resilience, with a quarterly revenue increase of 7.2% and a net profit increase of 22.5%, primarily driven by strong sales of innovative products [1] Group 1 - The new Employee Stock Ownership Plan (ESOP) is expected to provide greater visibility for growth and alleviate market concerns following leadership changes [1] - The company successfully completed two licensing agreements for independently developed molecules [1] Group 2 - Credit Lyonnais has raised its core profit forecast for Fosun Pharma for the years 2023 to 2027 by approximately 13% to 21% [1] - The target price for Fosun Pharma's H-shares has been increased from HKD 15.6 to HKD 29.6, while maintaining an "outperform" rating [1]

Core Points - The company has established a 2025 Employee Stock Ownership Plan (ESOP) to enhance the alignment of interests between employees and shareholders, improve corporate governance, and boost employee motivation and creativity for sustainable development [1][2] - The ESOP will be implemented in compliance with relevant laws and regulations, ensuring voluntary participation and risk-bearing by employees [2][3] - The total number of employees participating in the ESOP will not exceed 111, with a proposed share allocation of 640,000 shares for directors and senior management, representing 22.22% of the total shares [3][4] Summary by Sections Chapter 1: General Provisions - The ESOP is designed to comply with the Company Law, Securities Law, and other relevant regulations [1] Chapter 2: Formulation of the Employee Stock Ownership Plan - The purpose of the ESOP is to create a profit-sharing mechanism and enhance company competitiveness [2] - The plan adheres to principles of legality, voluntary participation, and risk-bearing by employees [2] Chapter 3: Funding Sources, Stock Sources, Purchase Price, and Scale - The total funds raised for the ESOP will not exceed RMB 27.216 million, with a maximum of 2.88 million shares available for purchase at a price of RMB 9.45 per share [6][8] - The shares will be sourced from the company's repurchased A-shares [7][8] Chapter 4: Duration, Lock-up Period, and Unlocking Arrangements - The ESOP will last for 80 months, with specific unlocking arrangements for shares based on performance metrics [10][11] Chapter 5: Participation in Company Financing - The management committee will decide on participation in financing activities during the ESOP's duration [13] Chapter 6: Management of the Employee Stock Ownership Plan - The ESOP will be managed by a management committee responsible for daily operations and safeguarding participants' rights [14][15] Chapter 7: Changes, Termination, and Rights Disposal - The ESOP can be modified or terminated based on the approval of the majority of participants [20][21] Chapter 8: Supplementary Provisions - The ESOP does not guarantee continued employment for participants, and tax liabilities will be borne by the employees [28][29]

Group 1 - The board of directors of Yuanli Chemical Group Co., Ltd. held its seventh meeting on August 27, 2025, with all nine directors present, ensuring compliance with legal and regulatory requirements [1] - The board approved the proposal for the 2025 semi-annual report and its summary, with a unanimous vote of 9 in favor [1] - The board also approved the proposal to cancel the supervisory board and amend the company’s articles of association, which will be submitted for review at the first extraordinary general meeting of shareholders in 2025 [2] Group 2 - The board approved the proposal for the 2025 employee stock ownership plan (draft) and its summary, with 6 votes in favor and 3 abstentions from related directors [3] - The board approved the proposal for the management measures of the 2025 employee stock ownership plan, with the same voting results as the previous proposal [3] - The board proposed to authorize the board to handle matters related to the 2025 employee stock ownership plan, which will also be submitted for review at the first extraordinary general meeting of shareholders in 2025 [4] Group 3 - The board proposed to convene the first extraordinary general meeting of shareholders in 2025, with a unanimous vote of 9 in favor [4]

Core Viewpoint - The company is set to implement a 2025 employee stock ownership plan aimed at enhancing employee motivation, cohesion, and overall competitiveness while promoting sustainable development and governance improvement [1] Summary by Relevant Sections - **Employee Stock Ownership Plan** The 2025 employee stock ownership plan is designed to establish a long-term and effective incentive mechanism, which will help in mobilizing employee enthusiasm and improving the company's competitiveness [1] - **Compliance and Governance** The plan adheres to relevant laws and regulations, including the Company Law and Securities Law of the People's Republic of China, and does not harm the interests of the company or its shareholders [1] - **Participation Principles** The plan follows principles of legality, voluntary participation, and risk-bearing by employees, ensuring there is no forced participation or distribution [1]

表决结果：3 票同意，0 票反对，0 票弃权。 元利化学集团股份有限公司 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、监事会会议召开情况 元利化学集团股份有限公司（以下简称"公司"）第五届监事会第六次会议 于 2025 年 8 月 27 日以现场及通讯表决方式召开。会议通知于 2025 年 8 月 22 日以电话及电子邮件方式通知全体监事。会议应参加监事 3 人，实际参加表决监 事 3 人。会议由监事会主席黄维君先生召集并主持，董事会秘书列席了本次会议。 会议的召开符合《公司法》及《公司章程》的规定，形成的决议事项合法、有效。 二、监事会会议审议情况 （一）审议通过了《关于公司<2025 年半年度报告>及摘要的议案》 监事会认为：公司《2025 年半年度报告》及其摘要的编制和审议程序符合 法律法规、中国证监会及上海证券交易所有关规定的要求，报告内容能够真实、 准确、完整地反映出公司报告期经营管理和财务状况，不存在任何虚假记载、误 导性陈述或者重大遗漏。在提出本意见前，未发现参与报告编制和审议的人员有 违反信息披露 ...